Education
About Us
Working with TipRanks
Follow Us
ChromaDex Corporation (CDXC)
NASDAQ:CDXC
CDXC Stock Chart & Stats
Day’s Range― - ―
52-Week Range$2.31 - $9.18
Previous CloseN/A
Volume55.16K
Average Volume (3M)1.23M
Market Cap
$611.90M
Enterprise Value$254.35M
Total Cash (Recent Filing)$0.00
Total Debt (Recent Filing)$2.65M
Price to Earnings (P/E)73.5
Beta0.57
Next Earnings
May 07, 2025EPS Estimate
0.02Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.10
Shares Outstanding77,750,450
10 Day Avg. Volume2,817,099
30 Day Avg. Volume1,226,803
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)6.20
Price to Cash Flow (P/CF)18.00
P/FCF Ratio18.00
Enterprise Value/Market Cap0.42
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit4.13
Enterprise Value/Ebitda28.73
Forecast
1Y Price Target
$9.03Price Target Upside16.67% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering3
---
Bulls Say, Bears Say
Bulls Say
Earnings PerformanceChromaDex reported impressive earnings outperformance with multiple revenue accelerants.
Market ExpansionNiagen Plus products are now available at over 475 leading wellness clinics in the U.S., indicating a massive expansion.
Strategic RebrandingChromaDex announced that it will change its corporate name to Niagen Bioscience, Inc. and trade under the new NASDAQ symbol 'NAGE', indicating a strategic rebranding effort.
Bears Say
Regulatory ChallengesIf the NO-PARK results prove positive, ChromaDex may explore the possibility of obtaining regulatory approval for a pharmaceutical-grade formulation of NR to treat Parkinson's disease.
Research And Development CostsThe company plans to continue investing in R&D to drive future innovation.
Sales And Marketing ExpensesSales and marketing expenses accounted for only 27.5% of net sales vs. 31% in the year-ago period.
---
Ownership Overview
29.85% Insiders
6.99% Mutual Funds
7.48% Other Institutional Investors
48.77% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
CDXC FAQ
What was ChromaDex Corporation’s price range in the past 12 months?
ChromaDex Corporation lowest stock price was $2.31 and its highest was $9.18 in the past 12 months.
What is ChromaDex Corporation’s market cap?
ChromaDex Corporation’s market cap is $611.90M.
When is ChromaDex Corporation’s upcoming earnings report date?
ChromaDex Corporation’s upcoming earnings report date is May 07, 2025 which is in 44 days.
How were ChromaDex Corporation’s earnings last quarter?
ChromaDex Corporation released its earnings results on Mar 04, 2025. The company reported $0.09 earnings per share for the quarter, beating the consensus estimate of $0.022 by $0.068.
Is ChromaDex Corporation overvalued?
According to Wall Street analysts ChromaDex Corporation’s price is currently Undervalued.
Does ChromaDex Corporation pay dividends?
ChromaDex Corporation does not currently pay dividends.
What is ChromaDex Corporation’s EPS estimate?
ChromaDex Corporation’s EPS estimate is 0.02.
How many shares outstanding does ChromaDex Corporation have?
ChromaDex Corporation has 77,750,450 shares outstanding.
What happened to ChromaDex Corporation’s price movement after its last earnings report?
ChromaDex Corporation reported an EPS of $0.09 in its last earnings report, beating expectations of $0.022. Following the earnings report the stock price went up 52.679%.
Which hedge fund is a major shareholder of ChromaDex Corporation?
Currently, no hedge funds are holding shares in CDXC
---
Chromadex Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$9.03 (16.67% Upside)
$9.03 (16.67% Upside)
Blogger Sentiment
Bullish
CDXC Sentiment 100%
Sector Average 69%
Sector Average 69%
Hedge Fund Trend
Increased
By 26.9K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $2.1K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▼ 0.4%
Last 30 Days ▲ 4.7%
Last 30 Days ▲ 4.7%
News Sentiment
Neutral
Bullish news 50%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Positive
20 days / 200 days
Momentum
185.60%
12-Months-Change
Fundamentals
Return on Equity
22.94%
Trailing 12-Months
Asset Growth
24.22%
Trailing 12-Months
Company Description
ChromaDex Corporation
Chromadex Corp. is a nutraceutical company, which engages in acquiring, developing, and commercializing proprietary-based ingredient technologies. It operates through the following segments: Ingredients, Consumer Products, and Analytical Reference Standards and Services. The Ingredients segment offers NIAGEN in an ingredient form to partners. The Consumer Products segment sells TRU NIAGEN to improve health by safely raising NAD levels. The Analytical Reference Standards and Services segment provides product regulatory approval and scientific advisory services to the clients in the food, supplement, and pharmaceutical industries. The company was founded by Mark S. Germain and Frank L. Jaksch, Jr. in September 1999 and is headquartered in Irvine, CA.
---
CDXC Company Deck
---
CDXC Earnings Call
Q4 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call reflects a strong financial performance with record revenues, increased cash flow, and improved operational efficiency. However, the company faces challenges in the supply chain and regulatory landscape, necessitating vigilance against market competitors' misleading practices. Overall, the positive financial results and strategic initiatives suggest a promising outlook despite these challenges.Read More>---
CDXC Stock 12 Month Forecast
Average Price Target
$9.03
▲(16.67% Upside)
Technical Analysis
Best Analysts Covering CDXC
1 Year
1 Year Success Rate
8/11 ratings generated profit
1 Year Average Return
+95.65%
reiterated a buy rating 20 days ago
Copying Sean McGowan's trades and holding each position for 1 Year would result in 72.73% of your transactions generating a profit, with an average return of +95.65% per trade.
---